Indirubin derivatives having heterobicyclic moieties and the use thereof
AssigneePelemed Co., Ltd.
InventorsSoo Yeon Jang, Myung Jin Kim, Jin Hee Park, So Deok Lee, Su Jin Oh, Eun Ji Lee, Yong Chul Kim, Woo Chan Kim, Je Heon Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel indirubin derivatives having heterobicyclic moieties, and use thereof as fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase inhibitors. The compound of the present invention effectively inhibits the activity of FLT3 and RET kinases, and thus may be useful for preventing or treating mutant FLT3 and mutant RET-related diseases, particularly acute myeloid leukemia.
Claims15
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of compounds 5, 9, 10, 11 and 13 below
- COM-
- POUND
- STRUCTURE
- NAME
- 4
- (2Z,3E)-3-((2- ((1R,4R)-2,5- diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)-[2,3′- biindolinylidene]-2′-on
- 5
- (2Z,3E)-3-((2-((1S,4S)- 2,5-diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)-[2,3′- biindolinylidene]-2′-on
- 9
- (2Z,3E)-3-((2- ((1R,4R)-2,5- diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)-5′- fluoro-[2,3′- biindolinylidene]-2′-on
- 10
- (2Z,3E)-3-((2-((1S,4S)- 2,5-diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)-5′- fluoro-[2,3′- biindolinylidene]-2′-on
- 11
- (2Z,3E)-3-((2- ((1R,4R)-2,5- diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)- 5′-chloro-[2,3′ - biindolinylidene]- 2′-on
- 13
- (2Z,3E)-3-((2- ((1R,4R)-2,5- diazabicyclo[2.2.1] heptane-2- yl)ethoxy)imino)- 5′-bromo-[2,3′- biindolinylidene]- 2′-on.
Dependencies are inferred from the claim text.